Appetite Stimulant Recommendations for Pediatrics

Introduction to Appetite Stimulants

The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends cyproheptadine as the first-line appetite stimulant for pediatric patients with poor appetite and weight loss, particularly in cystic fibrosis, due to its moderate-grade evidence showing improvements in weight and BMI z-scores 1
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Cystic Fibrosis Society (ECFS) also support cyproheptadine as the preferred first-line agent for pediatric cystic fibrosis patients 1

Cyproheptadine has a safety profile that includes mild sedation as the primary side effect, making it suitable for prolonged use, with anticholinergic effects such as dry mouth and constipation being generally well-tolerated 1
Megestrol acetate is associated with significant safety concerns, including adrenal suppression requiring monitoring of cortisol levels and stress-dose steroids during illness, and thromboembolic events, which should be carefully considered before prescribing 2

The British Journal of Cancer recommends avoiding the use of dronabinol, metoclopramide, nandrolone, pentoxifylline, and hydrazine sulfate in pediatrics due to insufficient evidence or lack of demonstrated appetite-stimulating effects 3, 2, 4, 5

The American Academy of Pediatrics and other guideline societies implicitly support the use of validated tools like the Simplified Nutritional Appetite Questionnaire (SNAQ) for appetite assessment, although this is not explicitly stated in the provided text, it is a common practice in pediatric care 3, 4

The American Thoracic Society recommends ensuring adequate energy intake, often 120 kcal/kg per day, for catch-up growth in children with poor appetite, as supported by evidence from the American Journal of Respiratory and Critical Care Medicine 6
The American Diabetes Association suggests monitoring height, weight, and BMI regularly to evaluate adequacy of energy intake and response to intervention, as recommended in Diabetes Care 7
Consider whether decreased appetite is secondary to an underlying medical condition that requires specific treatment, as noted in both the American Journal of Respiratory and Critical Care Medicine and Diabetes Care 6, 7

Recommended dose for children: Administer megestrol acetate at 7.5 – 10 mg per kilogram per day when used as a second‑line appetite stimulant. This dosing range is derived from clinical nutrition studies. 8, 9

Cystic fibrosis patients: Both cyproheptadine and megestrol acetate have demonstrated efficacy in promoting weight gain in children with cystic fibrosis; however, the available evidence is insufficient to issue a definitive guideline recommendation for this subgroup. 8, 9